Last reviewed · How we verify
NCT03185520: Y-ESUS
Young ESUS Patient Registry
trial in Embolic Stroke of Undetermined Source in 535 participants. Completed in 17 December 2020.
17 December 2020
Quick facts
| Lead sponsor | Population Health Research Institute |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 535 |
| Start date | 15 February 2017 |
| Primary completion | 17 December 2020 |
| Estimated completion | 17 December 2020 |
| Sites | 44 locations across France, South Africa, Chile, United Kingdom, Germany, Poland, Mexico, Argentina |
Conditions studied
- Embolic Stroke of Undetermined Source — all drugs for Embolic Stroke of Undetermined Source →
Sponsor
Population Health Research Institute
Who can join
Adults 21 to 50, any sex, with Embolic Stroke of Undetermined Source. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study seeks to determine the clinical characteristics of young ESUS patients using diagnostic criteria of the Cryptogenic Stroke / ESUS International Working Group, and to determine the rates of stroke recurrence, death, and hospital readmission in a contemporary cohort of young ESUS patients during follow-up of up to 18 months.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Main Abstracts.
· 2021 · cited 1× · PMID 35252582 · DOI 10.1177/23969873211034932 -
European Stroke Organisation Conference: Late Breaking Abstracts
· 2018
Verify or expand the search:
- PubMed search for NCT03185520
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Embolic Stroke of Undetermined Source
Currently open trials in the same condition.
- NCT07295769 — Atrial Fibrillation Detection Using MEMO Patch in Patients With Stroke of Unknown Cause · NA · recruiting
- NCT07224178 — Left Atrial Strain and Cryptogenic Stroke · recruiting
- NCT07479147 — SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation · recruiting
- NCT05238610 — Prospective Registry of Elderly ESUS With PFO · recruiting
- NCT06100718 — Discovery of New Cancer in the 1-year Follow-up After Ischemic Stroke in Patients at Risk: The INVISIBLE-1 Study · recruiting
Other Population Health Research Institute trials
Trials by the same sponsor.
- NCT07511543 — Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy · Phase 2 · not yet recruiting
- NCT07468448 — Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe · Phase 3 · not yet recruiting
- NCT06587737 — Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage · Phase 3 · not yet recruiting
- NCT07011095 — DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial · EARLY_PHASE1 · not yet recruiting
- NCT06508164 — International CRDS Registry · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03185520 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Population Health Research Institute
- Last refreshed: 4 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03185520.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing